MedTrace Logo

Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00054808 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2006-02-08

No results posted yet for this study

Summary

Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has progressed after standard chemotherapy. Patients will receive gallium nitrate 300 mg/m2/day by continuous IV infusion for 7 consecutive days using a portable infusion pump. Hospitalization is not required. Stable or responding patients will receive additional gallium nitrate infusions every 3 weeks until the time of disease progression, for a maximum total of 8 infusions, or 2 cycles after complete remission has been documented.

Conditions

  • Non-Hodgkin's Lymphoma
  • Relapsed Lymphoma
  • Refractory Lymphoma
  • Low-Grade Lymphoma
  • Intermediate-Grade Lymphoma

Interventions

DRUG

gallium nitrate

Sponsors & Collaborators

  • Genta Incorporated

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00054808 on ClinicalTrials.gov